Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 1, 2026

Warsh’s Return Revives Tensions Over the Fed’s $6.6 Trillion QE Hangover

View original at finance.yahoo.com
Warsh’s Return Revives Tensions Over the Fed’s $6.6 Trillion QE Hangover Photographer: Tierney L…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Demand for bank reserves and Fed balance sheet size is determined by banks' regulatory and internal liquidity needs

    80% confidence
  • Addition of another balance-sheet hawk on FOMC should help keep check on future asset purchases or reinvestment policies

    80% confidence
  • Fed can move short rate to offset balance sheet actions; shrinking balance sheet on principle allows offsetting rate cuts if long rates increase

    80% confidence
  • Run printing press less, let balance sheet come down, let Treasury handle fiscal accounts to achieve materially lower interest rates

    80% confidence
  • There is a bit of wiggle room within Fed definition of ample reserves

    80% confidence
  • Need new Treasury-Fed accord like 1951 where Fed chair and Treasury secretary describe objective for Fed balance sheet size to markets

    80% confidence
  • For now it's status quo, but markets will remain on edge until Warsh makes his views clearer

    80% confidence
  • Significantly smaller balance sheet would likely require major shift in Fed's existing bank regulatory framework

    80% confidence
  • If Warsh dislikes balance sheet expansion as a way to compress yields, then responsibility falls onto Treasury

    80% confidence
  • Aggressive bond buying artificially depressed borrowing rates for extended periods, fanned Wall Street risk-taking and encouraged lawmakers to pile on more debt

    80% confidence
  • Kevin Warsh has been very critical of the Fed's balance sheet expansion

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com